AR and prostate carcinoma: The androgen receptor (AR) signalling pathway is critical for the growth and survival of prostate cancer cells, including those of lethal castration‐resistant prostate cancer (CRPC), demonstrating that AR is a valid therapeutic target for treating prostate cancer.